Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

Abstract Background The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6–17 years) with autism spectrum disorder (ASD) in actual clinical sites of Japan. Methods In this post-marketing surveillance, pa...

Full description

Bibliographic Details
Main Authors: Yuna Sugimoto, Kayo Yamamura, Tomoyo Takayama, Yasuhiko Fukuta, Kazuo Aoki, Katsunaka Mikami, Akemi Tomoda
Format: Article
Language:English
Published: BMC 2021-04-01
Series:BMC Psychiatry
Subjects:
Aripiprazole
Autism spectrum disorder
Children and adolescents
Irritability
Post-marketing surveillance
Online Access:https://doi.org/10.1186/s12888-021-03201-6

Internet

https://doi.org/10.1186/s12888-021-03201-6

Similar Items